An intraocular lens (IOL) having an optical axis extending in an anterior-posterior direction and an equator extending in a plane substantially perpendicular to the optical axis is described. The IOL includes: an elastic anterior face located anterior to the equator; a posterior face located posterior to the equator, wherein the anterior face, the posterior face, or both comprises a poly(dimethylsiloxane) elastomer having a durometer between about 20 Shore A to about 50 Shore A; and a chamber located between the anterior face and the posterior face comprising a silicone oil comprising polysiloxanes comprising diphenyl siloxane and dimethyl siloxane units, the silicone oil having a maximum viscosity of about 800 cSt at 25° C.

The present invention resides in a method for producing jellyfish collagen hydrogels and kits for producing the same. The jellyfish collagen hydrogels can be used in the culture of cells. According to the invention, there is a process for producing jellyfish collagen hydrogels comprising jellyfish collagen fibrils, said process comprising the steps of: mixing a solution of purified jellyfish collagen and an aqueous neutralisation buffer; and incubating the mixture for a sufficient time to enable jellyfish collagen fibrils to form, wherein a cross-linking agent is either added during to mixing step or during or after the incubation of the mixture.

This invention includes a wettable biomedical device containing a high molecular weight hydrophilic polymer and a hydroxyl-functionalized silicone-containing monomer.

One or more embodiments of the present invention are directed to a medical device having a textured surface with an arithmetical mean height value (Sa) below 3.0 μm and a developed interfacial area ratio (Sdr) above 1.0 and a density of peaks (Spd) above 1×10.sup.6 peaks/mm.sup.2; a process of preparing such a medical device using a microstructured template; and a method of treating a mammal with such a medical device.

The present invention relates to an ultra-thin film silk fibroin/collagen composite implant for tissue engineering and a manufacturing method therefor. The ultra-thin film silk fibroin/collagen silk fibroin/collagen composite implant according to the present invention has no cytotoxicity and can minimize the influence on cell growth, due to the combined use of a refined silk fibroin aqueous solution, collagen and various biomaterials, and thus can be widely used as an ultra-thin film implant for implanting.

The invention provides a method for producing a ciliary marginal zone stem cell induced to differentiate from a pluripotent stem cell, including either the following step (1) or step (2), or both of these steps: (1) a step of floating culturing cells obtained from a cell aggregate containing a ciliary marginal zone-like structure induced to differentiate from pluripotent stem cells, thereby obtaining a retinosphere; and (2) a step of collecting stage specific embryonic antigen-1 positive cells from cells obtained from a cell aggregate containing a ciliary marginal zone-like structure induced to differentiate from pluripotent stem cells.

The present invention relates in general to the field of drug delivery systems for treating ocular diseases in animals, and more specifically, to a drug delivery system and method of treating Infectious Bovine Keratoconjunctivitis (“IBK”) in cattle, commonly known as “pinkeye.” The drug delivery system and method may include a contact lens that has been infused with drugs for treating IBK, such as oxytetracycline, penicillin, streptomycin, tetracycline, gentamicin, cloxacillin or combinations thereof. The medicated contact lens may be placed in contact with the cornea and/or conjunctiva of the afflicted eye of the animal. Drugs are released from the medicated contact lens via diffusion into the cornea and/or conjunctiva of the eye. After treatment, the contact lens may harmlessly dissolve in the eye wherein it is washed away via tear secretions.

The invention provides methods and polymer-containing formulations for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (a) a nucleo-functional polymer is a biocompatible polyalkylene polymer substituted by (i) a plurality of —OH groups, (ii) a plurality of thio-functional groups —R.sup.1—SH wherein R.sup.1 is an ester-containing linker, and (iii) optionally one or more —OC(O)—(C.sub.1-C.sub.6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups. Formulations are provided containing a nucleo-functional polymer, a poly(ethylene glycol) polymer, and an aqueous pharmaceutically acceptable carrier, for use in the therapeutic methods.

Ocular lenses having UV absorbing properties are disclosed. The ocular lens comprises a hydrogel polymer comprising polymerised residues derived from a polymerisable UV absorber of formula (I):

U-L-Py  (I)

wherein: U is a UV absorbing moiety; L is a hydrophilic non-polyalkylene glycol linker comprising an anionic, a zwitterionic or a saccharide moiety; and Py is an ethylenically unsaturated polymerisable moiety.

Glaucoma can be treated by implanting an intraocular shunt into an eye. The eye has an anterior chamber and sclera. A shunt can be placed into the eye to establish fluid communication from the anterior chamber of the eye through the sclera, and a pharmaceutical or biological agent can be administered to the eye.